Focused Compounding Capital Management, LLC

Focused Compounding Capital buys 867,514 shares at $0.35 (2 transactions); prior PRKA buys showed +54225% and +81900% 90-day returns.

Focused Compounding Capital Management filed 2 separate purchases totaling 867,514 shares at $0.35 on 2025-02-14, increasing holdings to 31.32M shares (a 2.8% increase). This insider's prior trades at PRKA on 2024-09-04 and 2023-12-14 delivered exceptional 90-day returns of +54225.0% and +81900.0% respectively, demonstrating consistent success in timing entries at this ticker. The current purchase occurs while the stock trades at $205.00, which is 31.6% below its 52-week high, following a 1.9% gain over the past 30 days. The company reported quarterly revenue of $1,770,458.00 and net income of $193,041.00, though full-year net income was negative. The magnitude of this transaction, combined with the insider's demonstrated historical accuracy at this specific ticker, merits close investor attention.

Focused Compounding Capital Management bought 1,344,555 shares at $0.40; stake now 30,454,705 shares (+4.6%)

Focused Compounding Capital Management, LLC purchased 1,344,555 shares of PRKA at $0.40, expanding its holdings by 4.6% to 30,454,705 shares. The timing is notable: this insider's prior PRKA purchase (2023-12-14) achieved a +85900.0% 90-day return, and across all open-market trades, the insider shows a 100% win rate with an avg 90d return of +85900.0%. However, the current fundamental backdrop presents a headwind: PRKA posted negative full-year net income, annual revenue declined 11.0%, and the stock is down 33.2% from its 52-week high despite a 30-day bounce of 3.9%. The buy at $0.40 represents a small fraction of the current $200.00 price, but given the company's shrinking top line and unprofitability, the trade does not clearly offset structural concerns. Investors should monitor whether this renewed accumulation reflects confidence in a turnaround or is simply portfolio-driven positioning at depressed basis.